Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Observer-blind, Randomized Study to Assess the Safety and Immunogenicity of Heterologous Prime-boost COVID-19 Vaccines Regimens in Individuals Aged 18 to 65 Years in Mozambique and Madagascar.

NCT04998240 is registered in ClinicalTrials.gov with International Vaccine Institute as lead sponsor.

NCT NCT04998240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04998240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Observer-blind, Randomized Study to Assess the Safety and Immunogenicity of Heterologous Prime-boost COVID-19 Vaccines Regimens in Individuals Aged 18 to 65 Years in Mozambique and Madagascar.
Lead sponsor
International Vaccine Institute
Phase
Phase 2
Overall status
Unknown status
Start date
December 29, 2021
Completion date
February 28, 2024
Enrollment
360 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid19